<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>Parkinson’s Disease (PD) is one of the most frequent disorders of the central nervous system (CNS). PD is an age-related disease in that morbidity increases with age. The main symptoms of it are motor symptoms like bradykinesia, rigidity and resting tremor. These symptoms diminish the comfort of the patient’s life and may lead to immobility. Hence, rapid diagnosis and start of treatment are very important.</p>
<p>The pharmacotherapy of PD is difficult. PD involves an imbalance between the dopaminergic and cholinergic systems. Therefore, the mechanisms of action of currently available drugs are highly connected with the pathology of PD, and follow dopaminergic or anticholinergic control strategies. However, long-term use of many PD medications comes with serious side effects. Therefore, the search for new, more effective drugs involving different strategies to that current and having different targets is still on-going.</p>
</abstract>

Parkinson’s Disease (PD) is one of the most frequent disorders of the central nervous system (CNS). PD is an age-related disease in that morbidity increases with age. The main symptoms of it are motor symptoms like bradykinesia, rigidity and resting tremor. These symptoms diminish the comfort of the patient’s life and may lead to immobility. Hence, rapid diagnosis and start of treatment are very important.
The pharmacotherapy of PD is difficult. PD involves an imbalance between the dopaminergic and cholinergic systems. Therefore, the mechanisms of action of currently available drugs are highly connected with the pathology of PD, and follow dopaminergic or anticholinergic control strategies. However, long-term use of many PD medications comes with serious side effects. Therefore, the search for new, more effective drugs involving different strategies to that current and having different targets is still on-going.

The recent guidelines for pharmacotherapy of Parkinson’s Disease

Chair and Department of Pharmacology and Pharmacodynamics

Current Issues in Pharmacy and Medical Sciences

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

{"article-title":"The recent guidelines for pharmacotherapy of Parkinson\u2019s Disease"}

Parkinson’s Disease (PD) is one of the most frequent disorders of the central nervous system (CNS). PD is an age-related disease in that morbidity increases...

The recent guidelines for pharmacotherapy of Parkinson’s Disease

Pubblicato online: 02 set 2022

Pagine: 80 - 85

Ricevuto: 05 mar 2022

Accettato: 10 giu 2022

DOI: https://doi.org/10.2478/cipms-2022-0015

Parole chiave
Parkinson’s Disease (PD), pharmacotherapy of PD, Dopamine Agonists, Anticholinergic Drugs, future treatment of PD

© 2022 Tomasz Karabin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

The recent guidelines for pharmacotherapy of Parkinson’s Disease

Pubblicato online: 02 set 2022

Pagine: 80 - 85

Ricevuto: 05 mar 2022

Accettato: 10 giu 2022

DOI: https://doi.org/10.2478/cipms-2022-0015

Parole chiaveParkinson’s Disease (PD), pharmacotherapy of PD, Dopamine Agonists, Anticholinergic Drugs, future treatment of PD

© 2022 Tomasz Karabin et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Parole chiave
Parkinson’s Disease (PD), pharmacotherapy of PD, Dopamine Agonists, Anticholinergic Drugs, future treatment of PD